BiomX, Inc. Quarterly report pursuant to Section 13 or 15(d)

Stockholders Equity (Tables)

3 Months Ended

Mar. 31, 2023

Warrant

Issuance Date

Expiration Date

Exercise Price Per Share

Number of Shares of Common Stock Underlying Warrants

Private Placement Warrants

IPO (December 13, 2018)

December 13, 2023

11.50

2,900,000

Public Warrants

IPO (December 13, 2018)

October 28, 2024

11.50

3,500,000

2021 Registered Direct Offering Warrants

SPA (July 28, 2021)

January 28, 2027

5.00

2,812,501

Pre-Funded Warrants

February 27, 2023

0.001

2,776,428

11,988,929

	Three Months Ended March 31,
	2023		2022
Underlying value of Common Stock ($)		0.40		1.41
Exercise price ($)		0.40		1.41
Expected volatility (%)		94.3		85.3
Expected terms of the option (years)		6.11		6.11
Risk-free interest rate (%)		4.21		2.50

	For the Three Months Ended March 31, 2023
	Number of Options			Weighted Average Exercise Price		Aggregate Intrinsic Value
Outstanding at the beginning of period		4,769,441		$	2.93	$	40
Granted		1,543,000		$	0.40
Forfeited		(197,841	)	$	3.16
Exercised		-		$	-
Outstanding at the end of period		6,114,600		$	2.28	$	67
Exercisable at the end of period		2,971,229		$	3.08
Weighted average remaining contractual life of outstanding options – years as of March 31, 2023		4.95

Warrant

Issuance
Date

Expiration
Date

Exercise
Price
Per Share

Number of
Shares of
Common Stock
Underlying
Warrants

Private Warrants issued to scientific founders (see below)

November 27, 2017

2,974

	Three Months Ended March 31,
	2023		2022
Research and development expenses, net		87		258
General and administrative		88		357
		175		615